$-0.05 EPS Expected for Cytori Therapeutics, Inc. (CYTX); Laffer Investments Cut Its Cme Group (CME) Stake

April 23, 2018 - By Kurt Siggers

Cytori Therapeutics, Inc. (NASDAQ:CYTX) Logo

Laffer Investments decreased Cme Group Inc (CME) stake by 6.43% reported in 2017Q4 SEC filing. Laffer Investments sold 1,484 shares as Cme Group Inc (CME)’s stock rose 9.29%. The Laffer Investments holds 21,607 shares with $3.16B value, down from 23,091 last quarter. Cme Group Inc now has $55.90B valuation. The stock decreased 0.53% or $0.87 during the last trading session, reaching $164.21. About 529,344 shares traded. CME Group Inc. (NASDAQ:CME) has risen 37.71% since April 23, 2017 and is uptrending. It has outperformed by 26.16% the S&P500.

Analysts expect Cytori Therapeutics, Inc. (NASDAQ:CYTX) to report $-0.05 EPS on May, 10.They anticipate $0.21 EPS change or 80.77% from last quarter’s $-0.26 EPS. After having $-0.10 EPS previously, Cytori Therapeutics, Inc.’s analysts see -50.00% EPS growth. The stock increased 1.61% or $0.0046 during the last trading session, reaching $0.2898. About 254,624 shares traded. Cytori Therapeutics, Inc. (NASDAQ:CYTX) has declined 82.57% since April 23, 2017 and is downtrending. It has underperformed by 94.12% the S&P500.

Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions. The company has market cap of $17.86 million. The firm primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma. It currently has negative earnings. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.

Among 7 analysts covering Cytori Therapeutics (NASDAQ:CYTX), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Cytori Therapeutics had 13 analyst reports since August 8, 2015 according to SRatingsIntel. The rating was upgraded by Zacks to “Hold” on Friday, September 4. As per Monday, August 10, the company rating was maintained by TH Capital. Maxim Group maintained the shares of CYTX in report on Monday, July 10 with “Buy” rating. The rating was downgraded by B. Riley & Co on Tuesday, July 25 to “Neutral”. Maxim Group maintained Cytori Therapeutics, Inc. (NASDAQ:CYTX) on Friday, August 11 with “Buy” rating. The firm has “Buy” rating by Laidlaw given on Thursday, February 22. The firm earned “Buy” rating on Wednesday, May 31 by Maxim Group. The firm has “Buy” rating given on Saturday, August 8 by Maxim Group. The stock of Cytori Therapeutics, Inc. (NASDAQ:CYTX) earned “Buy” rating by Maxim Group on Friday, March 9. On Monday, July 24 the stock rating was maintained by Maxim Group with “Buy”.

Investors sentiment increased to 1.15 in Q4 2017. Its up 0.14, from 1.01 in 2017Q3. It improved, as 29 investors sold CME shares while 224 reduced holdings. 78 funds opened positions while 212 raised stakes. 265.76 million shares or 0.05% less from 265.89 million shares in 2017Q3 were reported. Illinois-based Glenview Savings Bank Trust Dept has invested 2.39% in CME Group Inc. (NASDAQ:CME). Sigma Planning, Michigan-based fund reported 3,488 shares. Calamos Limited Liability owns 1,430 shares or 0% of their US portfolio. Tocqueville Asset Limited Partnership owns 0.01% invested in CME Group Inc. (NASDAQ:CME) for 4,944 shares. Lombard Odier Asset (Switzerland) Sa owns 1,400 shares for 0.02% of their portfolio. Smithfield Company owns 0% invested in CME Group Inc. (NASDAQ:CME) for 239 shares. 450 were accumulated by Paradigm Asset Com Limited Liability Com. Wealthfront invested 0.02% of its portfolio in CME Group Inc. (NASDAQ:CME). Alphaone Inv Llc holds 1,000 shares. Price T Rowe Associate Incorporated Md holds 0.02% of its portfolio in CME Group Inc. (NASDAQ:CME) for 933,570 shares. Tci Wealth Advsrs has 0% invested in CME Group Inc. (NASDAQ:CME) for 47 shares. Sabal holds 119,402 shares. 167,287 were reported by Arizona State Retirement Systems. Trustco Bancorporation N Y has invested 0.27% in CME Group Inc. (NASDAQ:CME). Thrivent Fincl For Lutherans holds 0.01% of its portfolio in CME Group Inc. (NASDAQ:CME) for 13,824 shares.

Since December 18, 2017, it had 0 insider purchases, and 10 sales for $9.68 million activity. The insider Tobin Jack J sold 2,325 shares worth $354,051. 2,500 shares were sold by Pietrowicz John W., worth $402,550. The insider DUFFY TERRENCE A sold 20,000 shares worth $3.03M. On Thursday, February 15 the insider GEPSMAN MARTIN J sold $49,287. Shares for $1.14M were sold by MELAMED LEO on Monday, February 5. Piell Hilda Harris sold $539,452 worth of CME Group Inc. (NASDAQ:CME) on Tuesday, February 20. 2,400 CME Group Inc. (NASDAQ:CME) shares with value of $387,972 were sold by Sammann Derek.

Laffer Investments increased Alerian Mlp Etf (AMLP) stake by 624 shares to 1,783 valued at $19.24M in 2017Q4. It also upped Tcp Capital Corp stake by 14 shares and now owns 2,011 shares. Micron Technology was raised too.

Analysts await CME Group Inc. (NASDAQ:CME) to report earnings on April, 26 before the open. They expect $1.85 earnings per share, up 51.64% or $0.63 from last year’s $1.22 per share. CME’s profit will be $629.76 million for 22.19 P/E if the $1.85 EPS becomes a reality. After $1.12 actual earnings per share reported by CME Group Inc. for the previous quarter, Wall Street now forecasts 65.18% EPS growth.

Among 19 analysts covering CME Group (NASDAQ:CME), 11 have Buy rating, 1 Sell and 7 Hold. Therefore 58% are positive. CME Group had 64 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by Deutsche Bank on Friday, July 29 with “Buy”. The firm has “Underperform” rating by RBC Capital Markets given on Monday, February 8. The stock of CME Group Inc. (NASDAQ:CME) earned “Buy” rating by UBS on Friday, July 29. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Wednesday, July 5 report. As per Monday, June 12, the company rating was maintained by RBC Capital Markets. As per Monday, October 16, the company rating was maintained by RBC Capital Markets. Jefferies maintained it with “Buy” rating and $12800 target in Monday, July 10 report. Citigroup maintained the shares of CME in report on Thursday, October 19 with “Buy” rating. The firm earned “Neutral” rating on Friday, May 20 by Sterne Agee CRT. Goldman Sachs upgraded the shares of CME in report on Wednesday, February 7 to “Buy” rating.

CME Group Inc. (NASDAQ:CME) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: